×

Register now for access to the Parexel Biotech Content Hub

First Name
Last Name
Company Name
Job Title
Country
Thank you!
Error - something went wrong!
   

Venturing into a new era of CNS drug development to improve success

August 22, 2017

The CNS market is one of the largest and fastest growing markets in the biopharmaceutical industry. Yet, despite a growing global need for novel CNS treatments, development of therapies for CNS diseases has lagged behind other areas. In this article, experts from Parexel’s BioPharm Unit identify three strategies that apply multidisciplinary solutions earlier in the development process to reduce failures and accelerate CNS drug development.

We are at the beginning of an era when CNS drug development requires both flexibility and creativity on the part of drug developers. For those involved in CNS drug development, the opportunities are significant.

Previous Flipbook
The hidden value of early patient centricity: practical solutions for early phase trials
The hidden value of early patient centricity: practical solutions for early phase trials

Learn about five economical and efficient ways to make early phase trials both patient-centric and more eff...

No More Flipbooks